DataString Consulting Company Logo
DataString Consulting Company Logo
Clindamycin Phosphate Market
Home»Recent Reports»Clindamycin Phosphate Market

Clindamycin Phosphate Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802111, Published - March 2025

Segmented in Product Type (Topical Solutions, Oral Suspensions, Injectables), Application (Skin Infections, Respiratory Infections, Intra-abdominal Infections, Others), Concentration, Industry Use, End-User and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Clindamycin Phosphate Market Outlook

The market, for Clindamycin phosphate was estimated at $930.0 million in 2024; and it is anticipated to increase to $2.1 billion by 2030 with projections indicating a growth to around $4.0 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 14.2% over the forecast period. The major growth in this area is mainly driven by the increasing occurrence of bacterial infections and skin conditions worldwide that have made clindamycin phosphate a highly valuable medication option for many people in need of treatment assistance. The strong demand for this antibiotic is also supported by its remarkable effectiveness and ease of use across various treatment plans. Factors like improved healthcare facilities and services around the world along with the growing concerns related to dermatology issues and increasing disposable income levels have all contributed to the continued importance of clindamycin phosphate, in the global market.


Clindamycin phosphate is a known of antibiotic that is used to treat severe and recurring infections caused by specifics of bacteria that include gram positive aerobes and various anaerobic bacteria strains due to its ability to inhibit bacterial growth effectively. In the field of dermatology it has shown progress as a topical treatment for acne which is in high demand due to the increasing focus, on maintaining aesthetic appearance and skin health.


Market Size Forecast & Key Insights

2019
$930M2024
2029
$3.5B2034

Absolute Growth Opportunity = $2.6B

The Clindamycin Phosphate market is projected to grow from $930.0 million in 2024 to $3.51 billion in 2034. This represents a CAGR of 14.2%, reflecting rising demand across Topical Treatments in Dermatology, Formulation in Lotions, Gels, and Foams and Combination Therapy for Bacterial Infections.

The Clindamycin Phosphate market is set to add $2.6 billion between 2024 and 2034, with manufacturer targeting Respiratory Infections & Intra-abdominal Infections Application projected to gain a larger market share.

With Surge in acne treatments, and Combatting bacterial infections, Clindamycin Phosphate market to expand 277% between 2024 and 2034.

Opportunities in the Clindamycin Phosphate Market

Strategic Collaborations in Emerging Markets

Partnerships between drug companies and research organizations can speed up the process of expanding the use of clindamycin medications for various purposes such as treating acne in countries, like India or China where the demand is increasing rapidly.

Development of Novel Treatment Regimens and Leveraging Technological Innovations

The medical field is facing challenges with acne that doesnt respond to antibiotics well these days. They are exploring new ways to treat it with clindamycin phosphate which is showing promise as a potential treatment option, for moderate to severe acne cases by combining it with other medications to enhance its effectiveness and expand its applications.

Dermatology is advancing quickly thanks to technologies like nanoparticle technology and transdermal drug delivery systems in the world today. Combining these advancements with clindamycin phosphate has the potential to transform the way acne is treated. Improving how antibiotics are delivered boosting absorption rates. Minimizing side effects all point toward a possible surge in the popularity of this medication leading to a thriving market, for it.

Growth Opportunities in North America and European Union

European Union Outlook

In the European Union there is a growing need for clindamycin phosphate due to a established healthcare system and substantial investment in dermatology research efforts. The increasing prevalence of infections and skin conditions is driving the market forward with nations like Germany and the United Kingdom emerging as key centers for demand. Given the landscape and strict regulatory standards within the EU region there is an essential focus, on producing top notch clindamycin phosphate products to meet market requirements. Moreover the rise in government investment in healthcare and an emphasis on well being have spurred the growth of the market. The factors propelling this market encompass a rising demographic a growing inclination towards self care and a rise in antibiotic resistance necessitating the demand for viable alternatives, like clindamycin phosphate.

North America Outlook

The market for clindamycin phosphate in North America has experienced expansion due to a growing interest in skincare and the treatment of acne among consumers in the region. Established pharmaceutical companies play a role in manufacturing and promoting clindamycin phosphate products contributing to the markets upward trend. Moreover the rising incidence of skin issues among individuals in the U. S. presents promising prospects for the clindamycin phosphate sector, in this region. In the realm of competition companies strive to stand out through approaches like creating distinct products and enhancing technology, in medical delivery methods.

North America Outlook

The market for clindamycin phosphate in North America has experienced expansion due to a growing interest in skincare and the treatment of acne among consumers in the region. Established pharmaceutical companies play a role in manufacturing and promoting clindamycin phosphate products contributing to the markets upward trend. Moreover the rising incidence of skin issues among individuals in the U. S. presents promising prospects for the clindamycin phosphate sector, in this region. In the realm of competition companies strive to stand out through approaches like creating distinct products and enhancing technology, in medical delivery methods.

European Union Outlook

In the European Union there is a growing need for clindamycin phosphate due to a established healthcare system and substantial investment in dermatology research efforts. The increasing prevalence of infections and skin conditions is driving the market forward with nations like Germany and the United Kingdom emerging as key centers for demand. Given the landscape and strict regulatory standards within the EU region there is an essential focus, on producing top notch clindamycin phosphate products to meet market requirements. Moreover the rise in government investment in healthcare and an emphasis on well being have spurred the growth of the market. The factors propelling this market encompass a rising demographic a growing inclination towards self care and a rise in antibiotic resistance necessitating the demand for viable alternatives, like clindamycin phosphate.

Growth Opportunities in North America and European Union

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, China, United Kingdom, India, Germany are expected to grow at 12.8% to 17.0% CAGR

2

Emerging Markets : India, Brazil, South Africa are expected to grow at 9.9% to 14.9% CAGR

Market Analysis Chart

Clindamycin phosphate is an antibioticthat'sbeen in demand lately because of the rise in bacterial infections worldwide. Healthcare providers prefer using it due to its effectiveness against a range of diseases. Despite its popularity among professionals the downside of potential side effects, from prolonged use might hinder its market growth.

Recent Developments and Technological Advancement

November 2024

Sanofi Pharmaceuticals completed a phase 3 trial that demonstrated the successful use of clindamycin phosphate, in treating severe acne.

September 2024

The latest product, from Mylan Pharmaceuticals is a absorbing clindamycin phosphate gel that claims to work faster and deliver better results.

June 2024

Pizer Inc introduced an extensive customer rewards program for its clindamycin phosphate oral suspension product to emphasize the significance of adherent medication usage in combating infections.

Our recent study highlights major advancements in the clindamycin phosphate market area as a potent antibacterial medication renowned for its efficacy in combating various bacterial infections; there has been a notable surge in its popularity in recent times due to the growing prevalence of antibiotic resistant bacterial infections that necessitate the use of treatments such, as clindamycin phosphate.

Impact of Industry Transitions on the Clindamycin Phosphate Market

As a core segment of the Pharmaceutical industry, the Clindamycin Phosphate market develops in line with broader industry shifts. Over recent years, transitions such as Emergence of Online Pharmacies and Innovations in Drug Delivery Systems have redefined priorities across the Pharmaceutical sector, influencing how the Clindamycin Phosphate market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Emergence of Online Pharmacies:

The rise of digitalization has led to a shift in the pharmaceutical industry with the emergence of online pharmacies selling clindamycin phosphate—a frequently prescribed antibiotic drug. Online platforms offer convenience in buying and receiving orders while enabling users to compare prices from suppliers effortlessly. This evolution has presented opportunities for manufacturers of clindamycin phosphate but has also posed significant hurdles, for conventional physical pharmacies. The shift to sales has broadened the reach to distant areas where brick and mortar pharmacies might not only have had a significant presence before; this indicates a groundbreaking shift, in the sector.

2

Innovations in Drug Delivery Systems:

In the clindamycin phosphateindustry'srecent advancements lie a shift. The groundbreaking evolution of delivery mechanisms takes center stage. The shift towards gels and creams over oral forms marks a notable progression in treating skin conditions like acne and bacterial infections due, to their heightened efficacy. These fresh delivery approaches promise enhanced skin absorption levels and bioavailability while lowering exposure levels. Ultimately resulting in more effective treatment outcomes.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Clindamycin Phosphate market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Surge in Acne Treatments, and Advancements in Topical Antibiotics

The pharmaceutical industry heavily relies on clindamycin usage in dermatology due to its effectiveness in addressing severe acne issues being a key factor driving its growing popularity in the market today. Moreoverl the rise in acne cases among teenagers and adults has also significantly contributed to the widespread use of clindamycin phosphate as a treatment option. This antibiotic is also highly acclaimed for its capacity to halt the proliferation of bacteria that cause acne breakouts. Making it a preferred solution, for dermatologists and skincare professionals.
The increasing emphasis in the healthcare sector on improving well being and the effectiveness of medications has also led to a rise in the demand for clindamycin phosphate, in topical antibiotics markets.
Clindamycin phosphate is also a powerful antibacterial agent widely employed in the healthcare industry to stop the growth of bacteria strains that cause infections in humans. The increasing prevalence of infections and the pressing requirement for efficient antimicrobial treatments are also driving the need for clindamycin phosphate. Claforan is also an administered form of injectable clindamycin phosphate often recommended by medical practitioners to address severe bacterial infections such, as septicemia, pelvic inflammatory disease and certain strains of pneumonia.

Restraint: Regulatory Compliance Challenges

Meeting requirements can pose a major hurdle in the clindamycin phosphate market as pharmaceutical products must adhere to strict regulations and standards for safety and effectiveness in various regions. Given that clindamycin phosphate is a prescription antibiotic product subject to scrutiny by regulatory authorities like the US FDA or the European Medicines Agency necessitates rigorous clinical trials and maintaining product quality consistently. The dynamic nature of regulations and variations, across regions can impede market growth as compliance expenses may surpass potential gains.

Challenge: Rising Antibiotic Resistance

One of the factors influencing the clindamycin phosphate market is the rise in antibiotic resistance levels globally as highlighted by the World Health Organization . The diminished efficacy of used antibiotics such as clindamycin phosphate against bacterial infections directly affects their market demand and prompts the healthcare sector to explore substitute treatments hence constraining the future growth opportunities, for clindamycin phosphate products.

Supply Chain Landscape

Raw Material Procurement

Phosphoric Acid Supplier Industries

Organic Chemical Manufacturers

Intermediate Production

Chiracon GmbH

VIO Chemicals

API Synthesis
Pharmacia Corporation / Pfizer Ltd
Formulation & Packaging
Stiefel Laboratories / Teva Pharmaceuticals
Raw Material Procurement

Phosphoric Acid Supplier Industries

Organic Chemical Manufacturers

Intermediate Production

Chiracon GmbH

VIO Chemicals

API Synthesis

Pharmacia Corporation

Pfizer Ltd

Formulation & Packaging

Stiefel Laboratories

Teva Pharmaceuticals

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Acne Treatment
Pharmaceuticals
Perrigo Company plc
Incorporating clindamycin phosphate in topical solutions for effective yet mild treatment options
Bacterial Infections
Healthcare
Mylan N.V.
Utilizing clindamycin phosphate in the formulation of oral medication to combat severe bacterial infections
Prevention of Postoperative Infections
Medical
Fresenius Kabi
Using clindamycin phosphate as injectables to thwart off infections post major surgical operations
Malarial Treatment
Biotechnology
Pfizer Inc.
Proactively integrating clindamycin phosphate in a combative regime against resistant strains of malaria

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Clindamycin Phosphate market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Clindamycin Phosphate in Formulation in Lotions, Gels, and Foams, Combination Therapy for Bacterial Infections and Topical Treatments in Dermatology

Formulation in Lotions, Gels, and Foams

Clindamycin phosphate is commonly found in lotions and gels recommended by dermatologists for skin care purposes due to its versatility and easy absorption by the skin cells over a period of time. They are often used in products specifically designed for term topical applications by well known manufacturers such, as Allergan and G&W Laboratories in their line of dermatology products.

Combination Therapy for Bacterial Infections

Clindamycin phosphate is widely used in combination treatments for bacterial infections and is frequently paired with additional antibiotics such as benzoyl peroxide to enhance the effectiveness in addressing conditions caused by susceptible bacterias by extending the antibacterial reach and improving treatment results in a broader spectrum of bacteria control efforts. Leading companies like Mylan and Teva Pharmaceuticals are players, in this sector offering various antibiotic combination therapies.

Topical Treatments in Dermatology

Clindamycin phosphate is an antibacterial ingredient found in many topical skin treatments that effectively targets the bacteria responsible for causing acne known as Propioinibacterium acnes. It is also effective in treating conditions like rosacea and other skin infections due to its inflammatory properties. Major pharmaceutical companies like Galderma and Perrigo focus on creating clindamycin phosphate based solutions p creams and gels showcasing their strong presence, in the market.

Clindamycin Phosphate vs. Substitutes:
Performance and Positioning Analysis

Clindamycin phosphate, renowned for its antibacterial prowess, distinguishes itself from alternatives such as erythromycin by exhibiting superior stability and efficacy. Its unique market positioning is energized by consistent demands within the acne treatment sector, bolstering its potential for sustained growth. These Alternatives specially Sodium Sulfacetamide has experienced a rapid growth as detailed in our latest report.

Clindamycin Phosphate
  • Erythromycin /
  • Sodium Sulfacetamide /
  • Salicylic Acid
    Effective in treating acne, bacterial infections
    May cause skin irritation, allergic reactions
    Effective in treating a broad spectrum of bacterial infections, fewer side effects compared to similar antibiotics
    Higher risk of developing drug-resistant bacteria, potential for severe allergic reactions

Clindamycin Phosphate vs. Substitutes:
Performance and Positioning Analysis

Clindamycin Phosphate

  • Effective in treating acne, bacterial infections
  • May cause skin irritation, allergic reactions

Erythromycin / Sodium Sulfacetamide / Salicylic Acid

  • Effective in treating a broad spectrum of bacterial infections, fewer side effects compared to similar antibiotics
  • Higher risk of developing drug-resistant bacteria, potential for severe allergic reactions

Clindamycin phosphate, renowned for its antibacterial prowess, distinguishes itself from alternatives such as erythromycin by exhibiting superior stability and efficacy. Its unique market positioning is energized by consistent demands within the acne treatment sector, bolstering its potential for sustained growth. These Alternatives specially Sodium Sulfacetamide has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Clindamycin Phosphate market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Clindamycin Phosphate across Hospitals, Retail Pharmacies, and Online Pharmacies Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Pfizer Inc., Perrigo Company plc, and Allergan plc by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Procurement, Intermediate Production, and API Synthesis. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Clindamycin Phosphate segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Procurement (Phosphoric Acid Supplier Industries, Organic Chemical Manufacturers), Intermediate Production (Chiracon GmbH, VIO Chemicals), and API Synthesis. Our parallel substitute analysis examines Erythromycin, Sodium Sulfacetamide, and Salicylic Acid, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Pfizer Inc., Perrigo Company plc, and Allergan plc, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Clindamycin Phosphate market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Clindamycin Phosphate Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 1.06 billion
Revenue Forecast in 2034USD 3.51 billion
Growth RateCAGR of 14.2% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024930 million
Growth OpportunityUSD 2.6 billion
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024930 million USD
Market Size 20271.39 billion USD
Market Size 20291.81 billion USD
Market Size 20302.06 billion USD
Market Size 20343.51 billion USD
Market Size 20354.01 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredProduct Type, Application, Concentration, Industry Use, End-User
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledPfizer Inc., Perrigo Company plc, Allergan plc, Alvogen Inc., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Panacea Biotec Ltd., Sandoz Inc., Teva Pharmaceutical Industries Ltd., Hatchtech Pty Ltd. and Valeant Pharmaceuticals International Inc.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Clindamycin Phosphate Market Size, Opportunities & Strategic Insights, by Product Type

4.1Topical Solutions
4.2Oral Suspensions
4.3Injectables
Chapter 5

Clindamycin Phosphate Market Size, Opportunities & Strategic Insights, by Application

5.1Skin Infections
5.2Respiratory Infections
5.3Intra-abdominal Infections
5.4Others
Chapter 6

Clindamycin Phosphate Market Size, Opportunities & Strategic Insights, by Concentration

6.11%
6.22%
6.3Custom Concentrations
Chapter 7

Clindamycin Phosphate Market Size, Opportunities & Strategic Insights, by Industry Use

7.1Pharmaceuticals
7.2Research Institutions
Chapter 8

Clindamycin Phosphate Market Size, Opportunities & Strategic Insights, by End-User

8.1Hospitals
8.2Retail Pharmacies
8.3Online Pharmacies
8.4Others
Chapter 9

Clindamycin Phosphate Market, by Region

9.1North America Clindamycin Phosphate Market Size, Opportunities, Key Trends & Strategic Insights
9.1.1U.S.
9.1.2Canada
9.2Europe Clindamycin Phosphate Market Size, Opportunities, Key Trends & Strategic Insights
9.2.1Germany
9.2.2France
9.2.3UK
9.2.4Italy
9.2.5The Netherlands
9.2.6Rest of EU
9.3Asia Pacific Clindamycin Phosphate Market Size, Opportunities, Key Trends & Strategic Insights
9.3.1China
9.3.2Japan
9.3.3South Korea
9.3.4India
9.3.5Australia
9.3.6Thailand
9.3.7Rest of APAC
9.4Middle East & Africa Clindamycin Phosphate Market Size, Opportunities, Key Trends & Strategic Insights
9.4.1Saudi Arabia
9.4.2United Arab Emirates
9.4.3South Africa
9.4.4Rest of MEA
9.5Latin America Clindamycin Phosphate Market Size, Opportunities, Key Trends & Strategic Insights
9.5.1Brazil
9.5.2Mexico
9.5.3Rest of LA
9.6CIS Clindamycin Phosphate Market Size, Opportunities, Key Trends & Strategic Insights
9.6.1Russia
9.6.2Rest of CIS
Chapter 10

Competitive Landscape

10.1Competitive Dashboard & Market Share Analysis
10.2Company Profiles (Overview, Financials, Developments, SWOT)
10.2.1Pfizer Inc.
10.2.2Perrigo Company plc
10.2.3Allergan plc
10.2.4Alvogen Inc.
10.2.5Hikma Pharmaceuticals PLC
10.2.6Glenmark Pharmaceuticals Ltd.
10.2.7Dr. Reddy's Laboratories Ltd.
10.2.8Panacea Biotec Ltd.
10.2.9Sandoz Inc.
10.2.10Teva Pharmaceutical Industries Ltd.
10.2.11Hatchtech Pty Ltd.
10.2.12Valeant Pharmaceuticals International Inc.